Ambeed.cn

首页 / / / / PMX-53

PMX-53

货号:A1150801 同义名: 3D53

PMX-53是一种有效的 C5a 受体拮抗剂,IC50 为 20 nM,具有抗炎,抗癌和抗动脉粥样硬化的活性。PMX-53 也是一种 MrgX2 激动剂,刺激 MrgX2 介导的肥大细胞脱颗粒。

PMX-53 化学结构 CAS号:219639-75-5
PMX-53 化学结构
CAS号:219639-75-5
PMX-53 3D分子结构
CAS号:219639-75-5
PMX-53 化学结构 CAS号:219639-75-5
PMX-53 3D分子结构 CAS号:219639-75-5
规格 价格 库存 数量
5mg ¥1260 咨询
10mg ¥1858 咨询
25mg ¥3780 咨询
购物车0 收藏 询单

PMX-53 纯度/质量文件 产品仅供科研

货号:A1150801 标准纯度:
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025, 188, (21): 5847-5861.e11. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025, 20, 1502-1513. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

PMX-53 生物活性

描述 PMX 53 is a potent C5a receptor antagonist (IC50 = 20 nM). Also MrgX2 agonist, it stimulates MrgX2-mediated mast cell degranulation, also inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis.

PMX-53 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Rats Infantile spasms model Subcutaneous injection 0.6 mg/kg Once daily for 4 days To evaluate the therapeutic effect of PMX53 on infantile spasms, results showed PMX53 significantly reduced the number of spasms Sci Rep. 2018 Apr 10;8(1):5722
Rats Reverse passive Arthus reaction model Oral, intravenous or topical 1 – 10 mg/kg Single dose, 30 min prior (oral) or 10 min prior (intravenous or topical) Inhibited immune-complex mediated dermal vascular leakage and systemic cytokine production Br J Pharmacol. 2001 Dec;134(8):1778-86
Mice MC-38 colorectal cancer model Intravenous injection 1 mg/kg Every other day until the end of the experiment Evaluated the antitumor effect of PMX-53, demonstrating that PMX-53 suppressed CRC growth by modulating gut microbiota and TLR5/AKT2 pathway to promote M1 polarization. Cell Death Dis. 2024 Feb 8;15(2):120
Mice NASH model Intraperitoneal injection 1 mg/kg Every other day for 4 weeks To evaluate the effect of PMX-53 on liver inflammation and fibrosis in NASH mice J Gastroenterol. 2023 Sep;58(9):894-907
Mice Chronic graft-versus-host disease (cGVHD) model Intraperitoneal injection 1 mg/kg Every three days PMX53 treatment attenuated the pathology of cGVHD, improved the survival rate of mice, and increased the frequency of Treg and expression of TGF-β1 Sci Rep. 2017 Jun 15;7(1):3603
Mice K14-HPV16 transgenic mice Subcutaneous implantation 1.0 mg/kg/day Once daily for 28 days PMX-53 in combination with paclitaxel significantly slowed the growth of squamous cell carcinomas, increased infiltration and cytotoxic properties of CXCR3+ effector memory CD8+ T cells Cancer Cell. 2018 Oct 8;34(4):561-578. e6
Mice Bullous pemphigoid model Intraperitoneal injection 200 µg/mouse Daily for 12 days To evaluate the effect of PMX-53 in prophylactic and therapeutic settings, results showed reduced skin lesions in prophylactic but not therapeutic approach. Front Immunol. 2018 Mar 15;9:488
Mice Hind paw incision model Subcutaneous injection 30 mcg/paw 2 hours before surgery and daily 2 hours before behavioral testing PMX53 reduced incisional mechanical and heat nociceptive sensitization regardless of neutrophil depletion Anesthesiology. 2012 Sep;117(3):602-12
Mice Hind paw incisional model Intraplantar injection 30 μg/15 μl Injected 1 hour before incision and then 2 hours before each test session To evaluate the effect of PMX53 on incision-induced heat hyperalgesia and mechanical allodynia, results showed that PMX53 significantly attenuated heat hyperalgesia and mechanical allodynia induced by hind paw incision J Neuroinflammation. 2011 Jul 7;8:80
Rats and mice Mechanical hypernociception model Intraplantar injection (rats), subcutaneous injection (mice) 60–180 μg per paw (rats), 0.3–3 mg/kg (mice) Single administration, observed for 1–24 h PMX53 inhibited hypernociception induced by zymosan, carrageenan, LPS, and antigen, associated with C5a receptor blockade Br J Pharmacol. 2008 Mar;153(5):1043-53

PMX-53 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.12mL

0.22mL

0.11mL

5.58mL

1.12mL

0.56mL

11.16mL

2.23mL

1.12mL

PMX-53 技术信息

CAS号219639-75-5
分子式C47H65N11O7
分子量 896.09
SMILES Code O=C([C@H](CCCNC(N)=N)NC([C@H](CC1=CNC2=CC=CC=C21)NC([C@@H](CC3CCCCC3)NC([C@]4([H])CCCN54)=O)=O)=O)NCCC[C@H](NC([C@@H](NC(C)=O)CC6=CC=CC=C6)=O)C5=O
MDL No. MFCD07363866
别名 3D53
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

DMSO: 190 mg/mL(212.03 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 2.5 mg/mL(2.79 mM),配合低频超声,并水浴加热至45℃助溶

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
请依序添加每种溶剂:10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.32 mM); 澄清溶液
此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL。
生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
方案 二
请依序添加每种溶剂:10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.32 mM); 澄清溶液
此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。
2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
方案 三
请依序添加每种溶剂:10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.32 mM); 澄清溶液
此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。